Acne Scarring in Skin of Color: Laser vs Microneedling

Status Withdrawn

Clinical Trial Summary

Atrophic acne scars are a common and important sequelae of acne that affect up to 43-55% of patients with acne. Scarring impacts quality of life with reports of diminished self-esteem and frustration/sadness; additionally, some individuals report that their appearance even interferes with their professional lives. Though many treatments for acne scarring exist including ablative and nonablative lasers, subcision, and peels, none is without risk of adverse effects of pain, post-procedure redness or pigmentary changes. There have been no randomized studies directly comparing the effectiveness and safety profiles of microneedling (Dermapen) to 1,540nm nonablative fractional lasers (Palomar StarLux) in the treatment of atrophic acne scarring in skin of color. This clinical trial aims to determine which treatment modality -- microneedling or nonablative fractional laser -- is safer and more efficacious in the treatment of acne scarring in patients with skin of color.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03395678
Study type	Interventional
Source	Boston University
Contact
Status	Withdrawn
Phase	N/A
Start date	November 2019
Completion date	December 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04321070` - Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris	Phase 1
Recruiting	`NCT05755256` - The Impact of Probiotics on Skin Hydration in Youth With Mild Acne	Phase 2
Completed	`NCT05131373` - Safety, Tolerability, and Immunogenicity of ORI-A-ce001 for the Treatment of Acne Vulgaris	Phase 1
Completed	`NCT01445301` - Study STF115287, a Clinical Confirmation Study of GSK2585823 in the Treatment of Acne Vulgaris in Japanese Subjects	Phase 3
Completed	`NCT03303170` - Non-Significant Risk Study of Sebacia Microparticles in the Treatment of Facial Acne Vulgaris	N/A
Completed	`NCT04698239` - Clinical Evaluation of the Safety and Benefits of the Milesman 445 nm Blue Laser on Inflammatory Acne Lesions.	N/A
Completed	`NCT02886715` - A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris	Phase 3
Terminated	`NCT02924428` - Venus Versa Diamondpolar Applicator Treatment Followed by AC Dual Applicator Treatment for Facial Acne Vulgaris	N/A
Not yet recruiting	`NCT02535871` - A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris	Phase 3
Completed	`NCT02709902` - Study Comparing Adapalene/BP Gel to EPIDUO® FORTE and Both to a Placebo Control in Treatment of Acne Vulgaris	Phase 1
Not yet recruiting	`NCT02491060` - A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris	Phase 3
Not yet recruiting	`NCT02525822` - Study to Compare the Safety and Efficacy of IDP-123 Lotion to Tazorac Cream in the Treatment of Acne Vulgaris	Phase 2
Completed	`NCT02913001` - The Effect of a Low Glycemic Load Diet on Hormonal Markers Associated With Acne	N/A
Completed	`NCT02250430` - A Phase 1 Study Assessing Local Cutaneous Effects of SB204	Phase 1
Completed	`NCT01694810` - Cutaneous Tolerability and Safety of NVN1000 Topical Gel in Healthy Volunteers	Phase 1
Completed	`NCT01769664` - A Study Comparing Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel to Duac® Topical Gel in the Treatment of Acne Vulgaris	Phase 1
Completed	`NCT01727440` - Identifying the Genetic Predictors of Severe Acne Vulgaris and the Outcome of Oral Isotretinoin Treatment	N/A
Completed	`NCT01194375` - A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris	Phase 2
Completed	`NCT00991198` - The Role of Topically Dissolved Oxygen (TDO) to Ameliorate Signs of Photodamage	Phase 2
Completed	`NCT01706250` - U0289-401: Eight Week, Split-face, Study to Determine and Compare the Efficacy and Tolerability of MAXCLARITY™ II to PROACTIV™	Phase 4